8-K: Viatris Secures $3.5 Billion Amended Revolving Credit Facility

Viatris has entered into a second amended and restated revolving credit agreement, increasing its borrowing capacity to $3.5 billion.

Summary

• Viatris has finalized a second amended and restated revolving credit agreement, establishing a $3.5 billion revolving credit facility.
• This new facility replaces the existing $4 billion revolving credit agreement from July 1, 2021.
• The credit facility allows Viatris to borrow in U.S. dollars and alternative currencies, including Euro, Sterling, and Yen.
• It includes a $300 million subfacility for letters of credit and a $175 million sublimit for swingline borrowings.
• Proceeds from the facility will be used for general corporate purposes, including repaying the existing revolving credit facility.
• The facility is guaranteed by Mylan Inc., Utah Acquisition Sub Inc., and Mylan II B.V., and other subsidiaries that guarantee third-party debt over $500 million.
• Interest rates are based on SOFR, EURIBOR, TIBOR, or SONIA plus 1.10% per annum, or a base rate plus 0.10% per annum.
• The facility has a fee of 0.15% on the daily amount of the aggregate revolving commitments.
• The agreement includes a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00.
• The facility is scheduled to expire five years from the closing date.

Sentiment

Score: 7

Explanation: The document is a standard financial agreement, indicating a stable financial position and access to capital. The sentiment is positive due to the successful refinancing, but not overly enthusiastic as it is a routine financial transaction.

Positives

• The new credit facility provides Viatris with a substantial $3.5 billion in borrowing capacity.
• The ability to borrow in multiple currencies offers flexibility in managing international operations.
• The inclusion of subfacilities for letters of credit and swingline borrowings provides additional financial tools.
• The facility allows for additional commitments to be sought from lenders or other financial institutions.

Negatives

• The agreement includes a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00, which could restrict financial flexibility if not met.
• The facility fee of 0.15% on the daily amount of the aggregate revolving commitments adds to the cost of borrowing.

Risks

• Failure to comply with the financial covenant requiring a leverage ratio no greater than 3.75 to 1.00 could trigger an event of default.
• Fluctuations in interest rates based on SOFR, EURIBOR, TIBOR, or SONIA could impact borrowing costs.
• The facility is subject to customary default provisions, which could lead to termination of commitments and acceleration of borrowings.
• The facility is subject to customary grace periods and materiality thresholds, which could lead to uncertainty.

Future Outlook

The document does not contain specific forward-looking statements or guidance, but it establishes a framework for future borrowing and financial operations.

Management Comments

• Theodora Mistras, Chief Financial Officer, signed the report on behalf of Viatris Inc.

Industry Context

This announcement is typical for large pharmaceutical companies that require significant financial flexibility to manage operations, acquisitions, and debt obligations. The new facility provides Viatris with a stable source of funding and aligns with industry practices for managing liquidity.

Comparison to Industry Standards

• The $3.5 billion revolving credit facility is a common financial instrument for large pharmaceutical companies, similar to those used by peers like Teva Pharmaceuticals and Pfizer.
• The multi-currency borrowing option is also standard for companies with global operations, mirroring the practices of companies like Novartis and Sanofi.
• The leverage ratio covenant of 3.75 to 1.00 is within the typical range for companies in the pharmaceutical sector, although some may have slightly higher or lower ratios depending on their financial strategies.
• The interest rate structure based on SOFR, EURIBOR, TIBOR, or SONIA plus a margin is consistent with current market practices for syndicated loans.
• The inclusion of subfacilities for letters of credit and swingline borrowings is a standard feature in such credit agreements, providing additional flexibility for short-term financing needs.

Stakeholder Impact

• Shareholders will benefit from the increased financial flexibility and stability provided by the new credit facility.
• Employees will benefit from the continued financial stability of the company.
• Customers and suppliers will benefit from the company's ability to maintain operations and fulfill obligations.
• Creditors will benefit from the company's improved financial position and ability to meet its debt obligations.

Next Steps

• Viatris will utilize the new credit facility for general corporate purposes, including repaying the existing revolving credit facility.
• Viatris may seek additional commitments under the Revolving Credit Facility from lenders or other financial institutions.

Key Dates

Keywords

revolving credit facility, Viatris, credit agreement, borrowing, financing, debt, SOFR, EURIBOR, TIBOR, SONIA, leverage ratio, letters of credit, swingline borrowings